Two drugs gained approval for the treatment of Duchenne muscular dystrophy (DMD), a rare X-linked genetic neuromuscular disorder resulting from mutations in the DMD gene, which encodes dystrophin, a protein crucial for proper muscle function (Keam 2023f). This evidence concerns the gene DMD and Duchenne muscular dystrophy.